Cipla Results

The company is de-risking key product Abraxane in case the Goa plant FDA issue is not cleared immediately

Drug major Cipla on Friday said its consolidated net profit increased 12 per cent to Rs 797 crore for the second quarter ended September 30. The Mumbai-based drug maker had reported a consolidated net profit of Rs 709 crore in the July-September period of the previous fiscal. Its total revenue from operations rose to Rs 5,829 crore for the September quarter from Rs 5,520 crore in the year-ago period, Cipla said in a regulatory filing. In respect of the transfer of India-based US business undertaking, the board decided not to proceed with the proposed transfer, considering various factors, including the current operating environment, it added. Shares of the company were trading 0.5 per cent up at Rs 1,154.10 apiece on the BSE.

Stocks to Watch today: ITC, UPL, Zomato, Arvind, Bajaj Consumer Care, among others will release their Q1 earnings today.

Domestic revenue dips 8.4% as Covid-19 share of branded prescription business normalises; North American business up 10% to $155 million

Cipla Q1 results preview: Analysts attribute the likely dull performance due to the high base of last year, and the reduction in revenue contribution from Covid-19 therapies in the recent quarter.

The Covid-19 portfolio contributed 5-6 per cent of Cipla's turnover during peak Covid waves, the firm said

For the full fiscal, Cipla has posted a 4.7% jump in net profit to Rs 2,517 crore, revenue and Ebitda rose 13.6% and 6.4% respectively

Chairman Y K Hamied and Vice Chairman MK Hamied, who are non-executive directors and promoters, have sold 2,01,69,756 shares on Tuesday

Bargain buying in banking and auto counters amid better-than-expected Q3 results by Axis Bank and Maruti Suzuki pushed the index 367 points higher at 57,858 level at close

Mumbai headquartered pharma firm posted 20% growth in profit before tax for the first quarter of the current financial year to Rs 799 crore, on a 9% YoY growth in revenues to Rs 4,346 crore

Firm's domestic business did well, up 16% YoY during the quarter when Cipla launched licensed version of Gilead's remdesivir

Improving growth in North America will complement strong domestic sales

The net profit came down 33 per cent to Rs 246 crore, lower than Street expectations. Emkay Global had expected a 3 per cent dip in profit for the quarter.

Promising domestic sales, new launches in the US are keeping analysts positive

Profitability though got a boost with higher contribution from limited competition products in the US

Total income from operations stood at Rs 36.9797 billion. It was Rs 35.82 billion for the same period a year ago

Growth is expected to be strong in the March 2017-18 quarter (Q4) as well and in the current financial year

Revenue from North America fell 2 percent due to ongoing pricing pressures in the generics market

Cipla its scaling down its biotech business after a weak fourth quarter which saw Rs 61.79 crore loss. In the same quarter last fiscal the company had posted Rs 93 crore loss.While the loss declined on a year on year basis the result was way below street estimates which was anticipating Rs 200-300 crore quarterly profit. Income from operations rose 8 per cent to Rs 3582 crore largely led by growth in the US market but sales slowed down in India and other emerging markets.Impairment charge of Rs 260 crore in relation to its biotech business and litigation for certain products in the US contributed to the loss."Operationally the quarter was in line with our guidance ," Cipla's chief executive officer Umang Vohra said. He added that the reported 14 per cent Ebidta margin included the one off impact of impairment and forex loss. Vohra said the company will not manufacture biosimilars and will outsource production of or look for inlicensing opportunities. The company has also put on ...

Analysts on average had expected the firm would report a profit of Rs 345 crore